Drug may reduce risk of heart attacks and cut cancer deaths
More than 10,000 patients took part in a trial using the anti-inflammatory canakinumab, the results of which were presented at the European Society of Cardiology meeting in Barcelona, Spain recently.
The patients, all of whom had previously had a heart attack but had not been diagnosed with cancer, were treated with the drug once every three months, and monitored for up to four years.
